Related Experiment Video
Updated: Apr 15, 2026
09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
7.2K
Histone H3 peptide based LSD1-selective inhibitors.
Taeko Kakizawa1, Yosuke Ota2, Yukihiro Itoh2
1Department of Chemistry and Biochemistry, School of Advanced Science and Engineering, Waseda University, Shinjuku, Tokyo 169-8555, Japan.
Bioorganic & Medicinal Chemistry Letters
|April 2, 2015
Summary
Researchers developed novel histone H3 peptide inhibitors targeting LSD1. Peptide 1a, featuring a phenylcyclopropylamine moiety, demonstrated potent LSD1 selectivity, guiding future inhibitor development.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Molecular Biology
Background:
- Lysine-specific demethylase 1 (LSD1) is a key epigenetic regulator implicated in various diseases.
- Developing selective LSD1 inhibitors is crucial for therapeutic intervention.
- Histone peptides offer a scaffold for designing targeted enzyme inhibitors.
Purpose of the Study:
- To design and synthesize novel histone H3 peptide-based inhibitors targeting LSD1.
- To identify the most potent and selective LSD1 inhibitor among the synthesized candidates.
- To investigate the structure-activity relationship, particularly the role of peptide length.
Main Methods:
- Chemical synthesis of histone H3 peptide analogs.
- Biochemical assays to evaluate LSD1 inhibitory activity and selectivity.
- Structure-activity relationship studies, including truncation analysis.
Main Results:
- Several histone H3 peptide candidates were synthesized and evaluated.
- Peptide 1a, incorporating a phenylcyclopropylamine (PCPA) moiety at Lys-4, emerged as the most potent LSD1-selective inhibitor.
- Truncation studies confirmed the importance of specific peptide sequence lengths for optimal inhibition.
Conclusions:
- Histone H3 peptide-based inhibitors can be effectively designed to target LSD1.
- Peptide 1a represents a promising lead compound for further development of LSD1 inhibitors.
- The findings provide a foundation for optimizing peptide-based LSD1 inhibitors for therapeutic applications.
